Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

References

• Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10
   PubMed Web of Science ®Google Scholar
• Sueta CA, Chowdury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-7
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
   PubMed Web of Science ®Google Scholar
• Foley KA, Simpson RJ, Crouse JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81
   PubMed Web of Science ®Google Scholar
• Meyer JW, Schultz JS, O’Donnell JC, et al. Pattern and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 2005;8:601-12
   PubMed Web of Science ®Google Scholar
• McKenney JM. Optimizing LDL-C lowering with statins. Am J Ther 2004;11:54-9
   PubMedGoogle Scholar
• Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-25
   PubMed Web of Science ®Google Scholar
• Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008;14(Suppl S-b):S9-15
   PubMedGoogle Scholar
• Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of healthcare interactions. Soc Sci Med 2004;58:851-62
   PubMed Web of Science ®Google Scholar
• Gotto AM. Treating hypercholesterolemia: looking forward. Clin Cardiol 2003;26:121-8
   Web of Science ®Google Scholar
• Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Study). J Am Coll Cardiol 2009;54:293-302
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160
   Web of Science ®Google Scholar
• 4S Study Group. Randomized trial of cholesterol-lowering in 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Expert panel on detection evaluation and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   Google Scholar
• Grundy SM, Cleeman JI Merz CN, et al American Heart Association: National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials in the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Wood D, De Backer G, Faergeman O, et al Prevention of heart disease in clinical practice. Recommendations of the second joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-503
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K. et al European guidelines for cardiovascular disease prevention in clinical practice: executive summery. Eur Heart J 2007;28:2375-414
   PubMed Web of Science ®Google Scholar
• Lee S, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007;29:2365-73
   PubMed Web of Science ®Google Scholar
• Fonesca F, Ruiz A, Cardona-Muñoz E, et al.; DISCOVERY PENTA investigators. The DISCOVERY PENTA study: a direct statin comparison of LDL-C value – an evaluation of rosuvastatin therapy compared with atorvastatin. Curr Med Res Opin 2005;21:1307-15
   PubMed Web of Science ®Google Scholar
• Strandberg T, Feely J, Sigurdsson E. Twelve week, multicenter, randomized open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high risk adults: a DISCOVERY study. Clin Ther 2004;26:1821-33
   PubMed Web of Science ®Google Scholar
• Lins R, Matthys K, Billiouw J, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004;62:287-94
   PubMed Web of Science ®Google Scholar
• Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb 2006;13:108-13
   PubMed Web of Science ®Google Scholar
• European Atherosclerosis Society. The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600
   PubMed Web of Science ®Google Scholar
• Friedewald W, Levy D, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin Chem 1972;18:499-502
   PubMed Web of Science ®Google Scholar
• World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004;15:124-9
   PubMedGoogle Scholar
• LaRosa J, He J, Vipputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled studies. JAMA 1999;282:2340-6
   PubMed Web of Science ®Google Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-36
   PubMed Web of Science ®Google Scholar
• Colleran K, Richards A, Schafer K. Disparities in cardiovascular disease risk and treatment: demographic comparison. J Investig Med 2007;55:415-22
   PubMed Web of Science ®Google Scholar
• Jacobson T. Overcoming ‘ageism’ bias in the treatment of hypercholesterolemia review of safety issues with statins in the elderly. Drug Saf 2006;29:421-48
   PubMed Web of Science ®Google Scholar
• Gotto A. Statin therapy and the elderly: SAGE advice?. Circulation 2007;115:681-3
   PubMed Web of Science ®Google Scholar
• Bartlett C, Davey P, Dieppe P, et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomized trials of 1990 to 2001. Heart 2003;89:327-8
   PubMed Web of Science ®Google Scholar
• Davidson MH, Sun SX, Nag SS, et al. Risk factors for discontinuation of statin medications: evidence from a large national pharmacy claims database. Circulation 2007;116:II_847
   Web of Science ®Google Scholar
• McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007;41:1805-11
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO tablet) - Livalo Effectiveness and Safety (LIVES) Study. Japan Pharmacol Ther 2008;36:709-31
   Google Scholar
• Mukhtar R, Reid J, Reckless J-P. Pitavastatin. Int J Clin Pract 2005;59:239-52
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-96
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Katerina A, Ioannis V, et al. Simvastatin: two decades in a circle. Cardiovasc Ther 2008;26:166-78
   PubMed Web of Science ®Google Scholar
• Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7
   PubMed Web of Science ®Google Scholar
• Mölgaard J, Wärjerstam-Elf S, Olsson AG. Efficacy and safety of simvastatin for high risk hypercholesterolemia. Am J Cardiol 1999;83:1043-8
   PubMed Web of Science ®Google Scholar
• Brown W. The safety of statins. Curr Opin Lipidol 2008;19:558-62
   PubMed Web of Science ®Google Scholar
• Jones P, Davidson M, Stein E. STELLAR GROUP. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase – effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab Pharmacokinet 2002;17:449-56
   PubMedGoogle Scholar
• Stein E. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002;89:50-7C
   PubMed Web of Science ®Google Scholar